Evaluation of in-vitro activity of new quinolones, macrolides, and minocycline against Mycoplasma pneumoniae

2000 ◽  
Vol 6 (3) ◽  
pp. 148-150 ◽  
Author(s):  
Hideaki Ikejima ◽  
Hiroyuki Yamamoto ◽  
Kazuo Ishida ◽  
Mitsuo Kaku ◽  
Jingoro Shimada
Keyword(s):  
Mycoplasma Pneumoniae ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
New Quinolones

In Vitro Activity of New Quinolones against Anaerobic Bacteria

Drugs ◽  
1995 ◽  
Vol 49 (Supplement 2) ◽  
pp. 233-234
Author(s):  
Carl Erik Nord ◽  
Ann Lindmark ◽  
Ingela Persson
Keyword(s):  
Anaerobic Bacteria ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
New Quinolones

scholarly journals In Vitro Activity of a New Quinoline Derivative, ER-2, against Clinical Isolates of Mycoplasma pneumoniae and Mycoplasma hominis

2009 ◽  
Vol 53 (12) ◽  
pp. 5317-5318 ◽  
Author(s):  
Shilpakala Sainath Rao ◽  
Raghavachari Raghunathan ◽  
Malathi Raghunathan ◽  
Ramesh Ekambaram
Keyword(s):  
Mycoplasma Pneumoniae ◽  
Mycoplasma Hominis ◽  
Quinoline Derivative ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity

scholarly journals Comparative In Vitro Activities of the Investigational Fluoroquinolone DC-159a and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas

2008 ◽  
Vol 52 (10) ◽  
pp. 3776-3778 ◽  
Author(s):  
Ken B. Waites ◽  
Donna M. Crabb ◽  
Lynn B. Duffy
Keyword(s):  
Mycoplasma Pneumoniae ◽  
Antimicrobial Agents ◽  
Mycoplasma Hominis ◽  
Mycoplasma Genitalium ◽  
The Other ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Mycoplasma Fermentans

ABSTRACT The in vitro susceptibilities of 151 unique clinical isolates of Mycoplasma pneumoniae, Mycoplasma hominis, Mycoplasma fermentans, Mycoplasma genitalium, and Ureaplasma species to DC-159a, an investigational fluoroquinolone, in comparison with those to other agents were determined. Macrolides were the most active agents against M. pneumoniae and M. genitalium, whereas clindamycin was most active against M. hominis. DC-159a MICs were ≤0.5 μg/ml for all Mycoplasma species and ≤4 μg/ml for ureaplasmas. DC-159a was the most active fluoroquinolone tested against M. pneumoniae and M. fermentans, and it was second to moxifloxacin against the other species. It was bactericidal against 10 M. pneumoniae isolates and demonstrated killing of ≥99.9% of the inoculum at 24 h for 2 isolates. The excellent in vitro activity of DC-159a demonstrates its potential for use in the treatment of infections due to mycoplasmas and ureaplasmas.

scholarly journals In Vitro Activity of Telithromycin (HMR3647), a New Ketolide, against Clinical Isolates of Mycoplasma pneumoniaein Japan

2000 ◽  
Vol 44 (5) ◽  
pp. 1381-1382 ◽  
Author(s):  
Toshiyuki Yamaguchi ◽  
Yoichi Hirakata ◽  
Koichi Izumikawa ◽  
Yoshitsugu Miyazaki ◽  
Shigefumi Maesaki ◽  
...  
Keyword(s):  
Mycoplasma Pneumoniae ◽  
Clinical Studies ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Broth Microdilution

ABSTRACT The in vitro activity of telithromycin (HMR3647), a new ketolide, against Mycoplasma pneumoniae was determined by the broth microdilution test using 41 clinical isolates obtained in Japan, as compared with those of five macrolides (erythromycin, clarithromycin, roxithromycin, azithromycin, and josamycin), minocycline, and levofloxacin. Telithromycin was less potent than azithromycin, but it was more active than four other macrolides, minocycline, and levofloxacin; its MICs at which 50 and 90% of the isolates tested were inhibited were both 0.00097 μg/ml, justifying clinical studies to determine its efficacy for treatment of M. pneumoniae.

Sign in / Sign up

Export Citation Format

Share Document